KR

PUBLICATION

  • R&D
  • PUBLICATION

PUBLICATION

· Revealing the role of increased SK3 expression in sulfonylurea resistance triggered by prolonged exposure

Jung Gyu Park, Minseok Kim, Sungje Yoo, Sun Wook Hwang, Jongsoo Mok, Joonghoon Park & Keon Wook Kang

· Targeting NLRP3/NLRP1 Inflammasome: Preclinical Efficacy and Safety of INV-1498 for Osteoarthritis

Yurim Lee, Jung Gyu Park and Dongchul Lim
Event: OARSI World Cogress (April 24-27, 2025)

· G Protein-Coupled Estrogen Receptor-Mediated Anti-Inflammatory and Mucosal Healing Activity of a Trimethylpyridinol Analogue in Inflammatory Bowel Disease

Bhuwan Prasad Awasthi, Prakash Chaudhary, Dongchul Lim, Kiran Yadav, Iyn-Hyang Lee, Suhrid Banskota, Chhabi Lal Chaudhary, Ujjwala Karmacharya, Jiwoo Lee, So Myoung Im, YeonJu Nam, Ji Won Eun, Sungeun Lee, Ji-Min Lee, Eun Soo Kim, Chongsuk Ryou, Tae Hun Kim, Hee Dong Park, Jung-Ae Kim, Tae-gyu Nam, and Byeong-Seon Jeong

· Hair Growth Promoting Effects of 15-Hydroxyprostaglandin Dehydrogenase Inhibitor in Human Follicle Dermal Papilla Cells

Hye Won Lim, Hak Joong Kim , Chae Young Jeon, Yurim Lee, Mujun Kim, Jinsick Kim, Soon Re Kim, Sanghwa Lee , Dong Chul Lim, Hee Dong Park, Byung Cheol Park and Dong Wook Shin

· The Inhibition of Oxidative Stress-Mediated Cell Apoptosis by the Caspase Inhibitor (S)-3-((S)-2-(6-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)-1-oxoisoindolin-2-yl)butanamido)-4-oxo-5-(2,3,5,6- tetrafluorophenoxy)pentanoic Acid in Human Dermal Papilla Cells

Bomi Park, Daeun Kim, Yurim Lee, Seihyun Choi, HeeDong Park, Sanghwa Lee and Jaesung Hwang

· Discovery of 3-Phenyl Indazole-Based Novel Chemokine-like Receptor 1 Antagonists for the Treatment of Psoriasis

Bongki Ko, Yongsoo Jang, Seung-Hwa Kwak, Hyun You, Jeong-Hyun Kim, Jung-Eun Lee, Hee Dong Park, Soo-Kyung Kim, William A Goddard 3rd, Jung Hyun Han, Yong-Chul Kim

· Benzbromarone Induces Targeted Degradation of HSP47 Protein and Improves Hypertrophic Scar Formation

Jung Gyu Park, Dong Chul Lim, Jeong Hwan Park, Seoah Park, Jongsoo Mok, Keon Wook Kang and Joonghoon Park
Journal of Investigative Dermatology (2023)

· Escin Activates Canonical Wnt/b-Catenin Signaling Pathway by Facilitating the Proteasomal Degradation of Glycogen Synthase Kinase-3b in Cultured Human Dermal Papilla Cells

Jae Young Shin, Jaeyoon Kim, Yun-Ho Choi, Sanghwa Lee, and Nae-Gyu Kang

· Topical application of INV-10000001, a first-in-class HSP47 inhibitor, attenuates hypertrophic scar in porcine and rodent animal models

Jung Gyu Park, Joonghoon Park Ph D, Dong Chul Lim Ph D, Jongsoo Mok, Jeong Hwan Park, and Seoah Park
EVENT: AADA(American Academy of Dermatology Association) 2023, Poster ID 42915

· Identification of first-in-class HSP47 inhibitor and its suppressive role in fibrogenic and inflammatory activity in human keloid cells

Jung Gyu Park, Dong Chul Lim Ph D, Joonghoon Park Ph D, and Jongsoo Mok
EVENT: AADA(American Academy of Dermatology Association) 2023, Poster ID 42906

· Identification of first-in-class HSP47 inhibitor and its suppressive role in hypertrophic scars and keloids

Jung Gyu Park, Dong Chul Lim, Joonghoon Park, Jongsoo Mok, Jeong Hwan Park, Seoah Park
EVENT: ESDR606

· Synthesis and anticancer evaluation of 6-azacyclonol-2,4,6-trimethylpyridin-3-ol derivatives: M3 muscarinic acetylcholine receptor-mediated anticancer activity of a cyclohexyl derivative in androgen-refractory prostate cancer

Ujjwala Karmacharya, Prakash Chaudhary, Dongchul Lim, Sadan Dahal, Bhuwan Prasad Awasthi, Hee Dong Park, Jung-Ae Kim, Byeong-Seon Jeong

· 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation

Chhabi Lal Chaudhary, Dongchul Lim, Prakash Chaudhary, Diwakar Guragain, Bhuwan Prasad Awasthia, ,Hee Dong Park,Jung-Ae Kim, Byeong-Seon Jeong

  • Headquater T. +82(2)-6956-8680
  • R&D T. +82(42)-721-0012
  • E. contact@innovothera.com

Innovo Therapeutics Inc.

  • Headquater : 507, 38 Mapo-daero, Mapo-gu, Seoul, 04174, Korea
  • CEO : HeeDong Park
  • Business registration number : 379-86-01520
  • R&D : C-313, 17 Techno 4-ro, Yuseong-gu, Daejeon, 34013, Korea

Copyright © 2022 innovotherapeutics All rights reserved.